Global Mineral Supplements Market Will Grow At A CAGR Of 7.3% Over The Six-Year Forecast Period 2014-2020 Expected To Reach US$ 14.5 Mn

Researchmoz added Most up-to-date research on "Global Market Study on Mineral Supplements: Pharmaceuticals Remain Key Application, Adult Women Continue Maximum Consumption" to its huge collection of research reports.

With a thriving market for dietary supplements, the market for mineral supplements is also growing on a global level. Since mineral supplements specifically help to address mineral deficiency among people of all ages, the market has been witnessing increasing adoption rate since the past few years. Persistence Market Research indicates that the market for mineral supplements has promising growth prospects in the next few years.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=320891

PMR’s recently published report on the global mineral supplements market focuses on all the aspects related to the growth of the mineral supplements market during a six-year forecast period, 2014-2020. The key points covered in the report can be briefly summarized as the historic, current, and expected market size, drivers, restraints, growth pattern, trends, opportunities, segments, and regional market analysis. The report also provides extensive profiles of some of the leading companies operating in the mineral supplements market.

The market report bifurcates the global mineral supplements market on the basis of application and end-use. The segmentation section of the report provides an extensive analysis of all the segments as well as sub-segments, along with the attributes responsible for their market condition. The next portion is of regional analysis that covers the four key regional markets viz. North America, Europe, Asia Pacific, and rest of the world. The report thus provides important insights into the opportunities and limitations that lie in each geographical market. The last part elaborates the leading market companies that compete on the market landscape. The report also provides porters five forces analysis of the global mineral supplements market.

Research Methodology

To deduce the global mineral supplements market size, the report considers various aspects based on secondary research. Furthermore, key data points such as region-wise split and market split by product type, vehicle type, and distribution channel; and qualitative inputs from primary respondents have been incorporated to arrive at appropriate market estimates. The forecast presented in the report assesses the total revenue generated and expected revenue contribution in the global mineral supplements market.

The report begins with sizing the market in terms of value and volume for the base year, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, gathered data is triangulated via different analysis based on supply side and demand side drivers and other key dynamics of the global mineral supplements market. To develop the market forecast, Persistence Market Research has also conducted a factor analysis to understand the impact of various forces/factors on the target market. The report provides forecasts not only in terms of CAGR but also presents a detailed analysis based on key parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/global-market-study-on-mineral-supplements-pharmaceutical-to-be-the-largest-segment-by-2020-report.html/toc

Another key feature of this report is an analysis of the global mineral supplements market and the corresponding revenue forecast in terms of absolute dollar opportunity, usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global mineral supplements market. Further, to understand key segments in terms of their growth and overall global mineral supplements market performance, Persistence Market Research has developed a market attractiveness index to help providers identify existing market opportunities in the global mineral supplements market.

Some of the major companies operating in mineral supplements market:

- Glanbia Plc.
- Nu Skin Enterprises, Inc.
- E. I. du Pont de Nemours and Company.
- NBTY, Inc.
- Koninklijke DSM N.V.
- BASF SE, Bayer AG, Atrium Innovations Inc.
- Amway and Herbalife, Ltd.
- Other

South-East Asia Type 2 Diabetes Mellitus Therapeutics Market is Anticipated to Grow at a Robust CAGR of 6.3% During 2016-2023

Researchmoz added Most up-to-date research on "Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2023 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth" to its huge collection of research reports.

Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects in insulin secretion, insulin action, or a combination of these. Chronic hyperglycemia is associated with the long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. Prevalence of the disease has risen rapidly in recent decades in the assessed South-East Asia countries, primarily as a result of rising obesity, a major risk factor for type 2 diabetes mellitus (T2DM). This has resulted in a large and competitive market landscape, with a number of drugs vying for various market segments across multiple lines of therapy.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1354596

T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies.  Nevertheless, significant unmet need remains for products that can offer better glycemic control, as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.

Scope

The current T2DM market in South-East Asia contains novel products, including Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.

- What are the competitive advantages of the existing novel drugs?
- There are over 609 active pipeline molecules, with most of the late-stage investigational drug candidates featuring improved dosing regimens and administration routes compared with currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent in the pipeline?
-  Is there potential for pipeline molecules to address unmet needs within the T2DM market?

Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest in Phase III, at 62.1%, with the overall attrition rate for T2DM standing at 88.3%.

- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
- Over the 2016-2023 forecast period, the T2DM therapeutics market in South-East Asia is expected to increase in value at a CAGR of 6.3%, from $1.92 billion to over $2.96 billion.
- Which markets make the most significant contribution to the regional market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?

Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth over the forecast period, despite generic sales erosion resulting from patent expirations.

- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/type-2-diabetes-mellitus-therapeutics-in-southeast-asia-markets-to-2023-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth-report.html/toc

Reasons to buy

- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed product landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
- Discover trends in licensing and co-development deals concerning T2DM products, and identify the major strategic consolidations that have shaped the commercial landscape.

Latest Research Report on Positron Emission Tomography Global Industry Trends And Forecast 2014 - 2020

Researchmoz added Most up-to-date research on "Positron Emission Tomography Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2014 - 2020" to its huge collection of research reports.

Positron emission tomography (PET) is a nuclear medicine imaging procedure that is used to monitor various internal body organs and tissues in order to identify certain disease conditions. It is performed by using a small amount of radioactive substance called tracers which move through blood circulation and thus helps radiologists in identifying the area of concerns precisely. PET imaging procedure provides a better insight about the working condition of organs and tissues, size, shape and position. PET is most widely used by oncologists in order to diagnose various types of cancer; neurologists in order to diagnose neurological disorders and cardiologists in order to diagnose cardiovascular diseases. Ongoing developments in this area are likely to begin its use in other specialties as well. This is also performed in order to assess the progress of the treatment of certain diseases. This procedure is different from magnetic resonance imaging (MRI) and computed tomography (CT) as they only show the tissue structure and blood flow to and from organs. This imaging procedure is also being used in combination with other diagnostic technologies such as CT with an aim to provide more precise information about various neurological, cardiovascular and cancer diseases.

The market for positron emission tomography is growing worldwide owing to increasing incidences of various cancers, neurological and cardiovascular diseases; growing use of PET in combination with other diagnostic technology such as CT and MRI, ongoing technological developments and expanding applications of PET procedure. Uninterrupted developments and discovery of new tracers (radionuclides) are also driving the PET imaging market. In addition, advantages offered by PET over other imaging technologies also drive the market growth. High cost associated with PET equipment has been identified as one of the major factors restraining the PET market growth. PET being highly capital intensive encourages the refurbished market for PET equipment.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=212722

Among all geographies, North America with the highest healthcare spending represents the largest market for PET. Reimbursement policy is playing a key role in driving the market growth in the region. Reimbursement coverage of PET scanning in the U.S. by the Medicaid and Medicare for the Alzheimer\'s disease offers potential opportunities to companies operating in the North American region. In Asia-Pacific region, increasing awareness among medical fraternity regarding the nuclear imaging technologies is likely to drive the market growth. Asia-Pacific being a home for more than half of the world population represents a large pool of patients suffering from various cancers, neurological and cardiovascular diseases.

The presence of such large pool of patients attracts companies like GE Healthcare, Siemens Healthcare and Philips Healthcare to invest in the region. Boost in the medical tourism industry in the region has also been considered as one of the major factors driving the market growth. A large number of patients come from other countries for various treatment procedures that propel healthcare providers of this region to equip with technically advanced medical technologies.

The market for positron emission tomography is highly consolidated and is dominated by a few select numbers of players, namely, GE Healthcare, Philips Healthcare and Siemens Healthcare. These players collectively account for more than 80% of the market share. Positron Corporation, Segami Corporation, Spectrum Dynamics Ltd., Naviscan, Inc. and MedX Holdings Inc. are some other players operating in this market.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

- North America
- Asia Pacific
- Europe
- Rest of the World 

This report provides comprehensive analysis of

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=212722

Rising Incidence Combined With Increasing Prevalence Of Cancer Across The World Is The Major Factor Expected To Drive The Global Lymphoblastic Lymphoma Market During The Forecast Period From 2016 To 2024

Researchmoz added Most up-to-date research on "Lymphoblastic Lymphoma Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2014 - 2020" to its huge collection of research reports.

Lymphobalstic lymphoma is also known as non-hodgkin lymphoma a type of cancer that primarily affects lymphatic system. The lymphatic system comprises organs such as the thymus, bone marrow, spleen, and the lymph nodes (or lymph glands). Lymph nodes are connected by a network of tubes called lymphatic vessels that contain lymph fluid and lymphatic tissue is also found in other organs such as skin, lungs and stomach. Prevalence of lymphoblastic lymphoma is high in teenagers and children compared to adults. According to National Cancer Institute (NCI), lymphoblastic lymphoma is the third most common childhood malignancy, and lymphoblastic lymphoma accounts for approximately 7% of cancers in children younger than 20 years. In the United States, in 2013 about 800 new cases of lymphoblastic lymphoma are diagnosed each year.

Lymphoblastic lymphoma is an aggressive lymphoma. This means that it is fast-growing and needs treatment straight away with chemotherapy. The primary symptoms observed in lymphoblastic lymphoma are enlarged lymph nodes, enlarged spleen, thrombocytopenia, fatigue, dyspnea and others. The types of lymphoblastic lymphoma are overactive bladder syndrome, chlamydia, cervical cancer, polycystic ovary syndrome (PCOS), pelvic inflammatory diseases and others.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=216068

The lymphoblastic lymphoma is diagnosed by removing enlarged lymph nodes and examining with blood tests, x-rays and scans, lumbar puncture and bone marrow. The first line of treatment for lymphoblastic lymphoma consists of chemotherapy, radiotherapy, stem cell support and steroid therapy. Chemotherapy is the main treatment for lymphoblastic lymphoma usually treated more intensively than other types of lymphomas. The patients are primarily referred to a specialist centre for treatment and it is similar to the treatment for acute lymphoblastic leukaemia. The three types of chemotherapies are used against lymphoblastic lymphoma market such as induction chemotherapy, consolidation therapy and continuing therapy. The potential complications of lymphoblastic lymphoma include opportunistic infections, neutropenic fever (admit the patient), bleeding, and tumor lysis syndrome.

North America was observed to be the largest market for lymphoblastic lymphoma treatment and the major reasons behind this is the increasing prevalence of genetic diseases and advanced diagnostic facilities. In the U.S., the incidence of lymphoblastic lymphoma is roughly 3000-3500 or approximately 1 in 50,000 in 2012.  While currently it has peak the incident rate of 2–5 years old, decreasing in incidence with increasing age before increasing again at around 50 years old. Lymphoblastic lymphoma is slightly more common in males than females and an increased incidence in people with a family history of autoimmune diseases, particularly autoimmune thyroid diseases (namely Graves\' disease or Hashimoto\'s thyroiditis). Asia-Pacific were observed to be the most potential market as the developing healthcare facilities and acceptance of modern technology are enhancing the diagnostics of disease where the detection of lymphoblastic lymphoma is easily observed. The high investments were observed in the point of care sector of healthcare in the emerging markets such as India, China, Brazil, Mexico and others that are driving the market growth in these regions.

Some of the key players in this market are Novartis AG, Pfizer Inc., Sanofi SA, Jazz Pharmaceuticals plc, Bristol-Myers Squibb Company,  AstraZeneca PLC, Eisai Inc., Amgen Inc. and BioCryst Pharmaceuticals, Inc. Key players involved in the research and development are National Cancer Institute, Fred Hutchinson Cancer Research Center, The University of Texas M. D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center , St. Jude Children\'s Research Hospital, Inc., Johann Wolfgang Goethe University Hospitals and others.

This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

- North America
- Asia Pacific
- Europe
- Rest of the World

This report provides comprehensive analysis of

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Reasons for Buying this Report

- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=216068

Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals | Researchmoz

Researchmoz added Most up-to-date research on "Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals" to its huge collection of research reports.

GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for December 2015 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in December 2015. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=577339

Scope

- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=577339